European Commission Seeks To Facilitate Innovative Orphan Drug Entry; Avoid Delays For Generics
This article was originally published in SRA
Executive Summary
The European Commission has drafted an updated version of its 2003 communication on orphan drugs which, it says, should facilitate the market entry of innovative products and avoid delays to the entry of generics.